Structure-based multiparameter optimization yielded the medical candidate NVP-AUY922, now in Phase II trials (Brough et al., 2008; Eccles et al., 2008). This had a Kd of 2 nM, confirmed mechanism-based inhibition of cancer cell proliferation at ∼9 nM and exhibited potent antitumor activi...